SCHEMBL2591074

SCHEMBL2591074

Brc1ccc2nc(Cc3ccccc3)oc2c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.58
TP53 P04637 5/20 0.58
SMN1; SMN2 Q16637 2/20 0.58
MAPT P10636 5/20 0.50
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
POLB P06746 1/20 0.50
USP2 O75604 1/20 0.50
MAPK10 P53779 1/20 0.50
CHRNB2 P17787 1/20 0.50
CHRNA4 P43681 1/20 0.50
DAGLA Q9Y4D2 1/20 0.50
GPR119 Q8TDV5 1/20 0.49
MEN1 O00255 1/20 0.49
ELANE P08246 1/20 0.49
KMT2A Q03164 1/20 0.49
RXFP1 Q9HBX9 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
AKR1B1 P15121 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5077598 0.88 LMNA (0.58) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL4059497 0.86 MAPT (0.60) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL15688526 0.85 LMNA (0.51) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL4055949 0.85 MAPT (0.58) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL5077628 0.81 LMNA (0.60) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL3821992 0.81 SMN1; SMN2 (0.83) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL31683078 0.80 LMNA (0.61) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL4650036 0.80 TP53 (0.89) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL31683098 0.79 LMNA (0.55) LMNATP53SMN1; SMN2MAPTNPC1
SCHEMBL17955356 0.78 MAPT (0.47) LMNATP53SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2566864-B1 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INT (DE) 2014-09-03 EP disclosed
US-8772323-B2 Benzoxazole- and tetrahydrobenzoxazole-substituted pyridazinones as GPR119 agonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-07-08 US disclosed
US-20130172323-A1 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-07-04 US disclosed
EP-2566864-A2 PYRIDAZINONES AS GPR119 AGONISTS Boehringer Ingelheim International GmbH (DE) 2013-03-13 EP disclosed
WO-2011138427-A2 PYRIDAZINONES AS GPR119 AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172323-A1 PYRIDAZINONES AS GPR119 AGONISTS GPR65, GPR119, GPR55 LMNA 2866/4885TP53 4758/4885SMN1; SMN2 3910/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.